I don't know about anyone else, but to me the leas
Post# of 15624
(Total Views: 281)
Posted On: 04/07/2017 2:24:51 PM
I don't know about anyone else, but to me the least important part of the Annual Report is the accounting for the last year. The most important part is the company's assessment of where we are, and where we're going in the next year and beyond.
I don't believe that it's the financial portion of the report that's holding up it's release, I believe it's what they can say about the present, and future that is under continual development. I believe it's to early to speak about the safety trial, unless in fact they've been given a peek at what's happening there, if so, perhaps they can say something.
We've been concentrating on the psoriasis cream, perhaps the report will give us greater reason to also consider the sublingual tablet. I certainly don't know of anything as a fact about the tablet, but it appears to me that they feel confident that that product can launch this year as well, perhaps as quickly as the psoriasis cream. Could it be that the tablet essentially uses materials that have already been proven safe, and while they may have formulated them in a different manner that's protected by patents, no further safety or efficacy testing is required.
It's probably been about 50 years since I heard the story of how a group of engineers and scientists looked at how a color TV tube could be made. The group found four ways it could be done, and determined that three of the ways were patented and in production. I hope I've gotten the facts right, but as I remember the story, they patented the fourth way, and only after that did they build the picture tube. That's how the Sony Trinatron picture tube was created, and it proved superior to all the others. I tell this story as a way of saying the scientists at OWCP may not have invented any single part of what becomes their sublingual tablet, but they may have built it differently, patented it, and have a product that's truly superior to anything that's currently available as a way of administering perhaps several different forms of cannabis. Not only that, but perhaps because nothing really new is being tried, it can be marketed without substantial testing for either safety or efficacy.
Gary
I don't believe that it's the financial portion of the report that's holding up it's release, I believe it's what they can say about the present, and future that is under continual development. I believe it's to early to speak about the safety trial, unless in fact they've been given a peek at what's happening there, if so, perhaps they can say something.
We've been concentrating on the psoriasis cream, perhaps the report will give us greater reason to also consider the sublingual tablet. I certainly don't know of anything as a fact about the tablet, but it appears to me that they feel confident that that product can launch this year as well, perhaps as quickly as the psoriasis cream. Could it be that the tablet essentially uses materials that have already been proven safe, and while they may have formulated them in a different manner that's protected by patents, no further safety or efficacy testing is required.
It's probably been about 50 years since I heard the story of how a group of engineers and scientists looked at how a color TV tube could be made. The group found four ways it could be done, and determined that three of the ways were patented and in production. I hope I've gotten the facts right, but as I remember the story, they patented the fourth way, and only after that did they build the picture tube. That's how the Sony Trinatron picture tube was created, and it proved superior to all the others. I tell this story as a way of saying the scientists at OWCP may not have invented any single part of what becomes their sublingual tablet, but they may have built it differently, patented it, and have a product that's truly superior to anything that's currently available as a way of administering perhaps several different forms of cannabis. Not only that, but perhaps because nothing really new is being tried, it can be marketed without substantial testing for either safety or efficacy.
Gary
(0)
(0)